Ebvallo gets a second US knockback
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
The month ahead: January’s remaining events
JP Morgan approaches.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Takeda thins the cell therapy pipeline
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
